Compare · OCX vs ORKA
OCX vs ORKA
Side-by-side comparison of Oncocyte Corporation (OCX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OCX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $7.12B.
- ORKA has hit the wire 8 times in the past 4 weeks while OCX has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 9 for OCX).
- Company
- Oncocyte Corporation
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- -
- $7.12B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- AMEX
- NASDAQ
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 9
- 11
Oncocyte Corporation
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
Latest OCX
- InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors
- Director Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)
- Director Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)
- Director Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)
- Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Oncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
- Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
- SEC Form DEFA14A filed by Oncocyte Corporation
- SEC Form DEF 14A filed by Oncocyte Corporation
Latest ORKA
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
- General Counsel Quinlan Paul T sold $706,735 worth of shares (9,000 units at $78.53) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana sold $523,648 worth of shares (7,000 units at $74.81) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $805,889 worth of shares (9,999 units at $80.60) as part of a pre-agreed trading plan (SEC Form 4)